Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab.
OBJECTIVE
To report the rapid regression of extensive retinovitreal neovascularization following the administration of a single dose of intravitreal bevacizumab.


METHODS
A 60-year-old woman presented with recurrent vitreous hemorrhage originating from active retinovitreal neovascularization secondary to branch retinal vein occlusion. The neovascular tissue remained active despite multiple sessions of laser therapy. Intravitreal injection of 1.25 mg bevacizumab was performed.


RESULTS
Rapid regression of the retinovitreal neovascularization, a marked reduction in retinal vein engorgement, and visual improvement was observed 1 week after the intervention


CONCLUSIONS
Intravitreal bevacizumab can result in the rapid and dramatic regression of retinovitreal neovascularization refractory to previous laser photocoagulation.
Ahmadieh
Hamid
H
Department of Ophthalmology, Ophthalmic Research Center, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Boostan 9 St., Pasdaran Ave., Tehran, 16666, Iran. hahmadieh@hotmail.com
Moradian
Siamak
S
Malihi
Mohsen
M
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008875:Middle Aged; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000473:pathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body / Q000098:blood supply*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab